EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Telmisartan, an anti-hypertensive drug, impedes JEV infection, possibly via the AT1/PPARγ axis

Ankita Datey iD, Sanchari Chatterjee, Soumyajit Ghosh iD, P Sanjai Kumar, Saikat De iD, Udvas Ghorai iD, Debasish Hota, Bharat Bhusan Subudhi iD, Soma Chattopadhyay iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.03003-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Ankita Datey und 8 weiteren Autor:innen. Beteiligte Einrichtung: BRIC- Institute of Life Sciences, Bhubaneswar, Odisha, India. Hauptthemen laut MEDLINE: Telmisartan, PPAR gamma, Encephalitis Virus, Japanese, Encephalitis, Japanese. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Council of Scientific and Industrial Research, India, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Japanese encephalitis, caused by Japanese encephalitis virus (JEV), is a vector-borne disease with no specific therapeutics available yet. Binding of angiotensin II (Ang II) to angiotensin II type 1 (AT1) receptor induces the release of inflammatory cytokines associated with viral encephalitis. Accordingly, Ang II receptor blockers (ARBs) have been proposed to manage encephalitis. Since telmisartan (TM, antagonist of AT1 and agonist of PPARγ) has relatively better brain access than other ARBs, this investigation aims to evaluate its anti-JEV efficacy in vitro and in vivo . TM reduced JEV titer, RNA, and protein (NS3) significantly in the BHK-21 cells with an IC 50 of 24.68 µM and a CC 50 of >350 µM (Selectivity Index >14.18), indicating its potential for repurposing against JEV. The anti-JEV efficacy of TM was further observed in other physiologically relevant cells. Interestingly, the viral load was reduced significantly in pre-, co-, and post-treatment conditions of TM. In the presence of GW (PPARγ antagonist) and AG (AT1 agonist), viral infection was increased remarkably, while AT1 was upregulated and PPARγ was downregulated. TM treatment reversed these levels during infection. In addition, siRNA knockdowns of AT1 and PPARγ showed an insignificant change in infection upon TM treatment. Furthermore, reduction of inflammatory markers like p-IRF-3, COX-2, and p-NF-κB was observed after TM treatment in RAW264.7 cells, suggesting its immunomodulation through the AT1/PPARγ axis. Finally, the anti-JEV potential of TM was validated in a mouse model through the reduction of disease score, viral protein, and histological changes. Thus, the preclinical efficacy of TM suggests its suitability for repurposing against JEV. IMPORTANCE Japanese encephalitis, caused by JEV, is a vector-borne disease for which no specific therapeutics are yet available. Binding of Ang II to the AT1 receptor induces the release of inflammatory cytokines associated with viral encephalitis. Accordingly, telmisartan, which is an antagonist of AT1 and an agonist of PPARγ with better brain access, was evaluated for its anti-JEV efficacy in vitro and in vivo in the current study. Telmisartan demonstrated significant reduction in JEV titer, RNA, and protein levels in different treatment conditions. This treatment reversed the levels of AT1 and PPARγ as well as inflammatory markers, p-IRF-3, COX-2, and p-NF-κB during JEV infection, suggesting its immunomodulatory effect through the AT1/PPARγ axis. Finally, the anti-JEV potential of telmisartan was validated in a mouse model through the reduction of disease score, viral protein, and histological changes. Hence, the preclinical efficacy of telmisartan suggests its suitability for repurposing against JEV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelmisartanPPAR gammaEncephalitis Virus, JapaneseEncephalitis, JapaneseReceptor, Angiotensin, Type 1Antiviral AgentsAntihypertensive AgentsAnimalsMiceCell LineViral LoadDisease Models, AnimalHumans

Stichwörter der Autor:innen

AT1BHK-21 cellsHuh7 cellsJEVPPARγtelmisartan

Substanzen

TelmisartanPPAR gammaReceptor, Angiotensin, Type 1Antiviral AgentsAntihypertensive Agents

Autor:innen und Institutionen

  • BRIC- Institute of Life Sciences, Bhubaneswar, Odisha, India.
  • School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar, India.
  • Viral Mutation Section, HIV dynamics and Replication Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.
  • Regional Centre for Biotechnology, Faridabad, India.
  • Division of Neonatology and Newborn Nursery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Scripps Research, La Jolla, California, USA.

ORCID-Profile: Ankita Datey, Soumyajit Ghosh, Saikat De, Udvas Ghorai, Bharat Bhusan Subudhi, Soma Chattopadhyay

Förderung

  • Council of Scientific and Industrial Research, India
  • Indian Council of Medical Research

Zitieren

APA

Datey, A., Chatterjee, S., Ghosh, S., Kumar, P. S., De, S., Ghorai, U., Hota, D., Subudhi, B. B., & Chattopadhyay, S. (2025). Telmisartan, an anti-hypertensive drug, impedes JEV infection, possibly via the AT1/PPARγ axis. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03003-24

Vancouver

Datey A, Chatterjee S, Ghosh S, Kumar PS, De S, Ghorai U, et al. Telmisartan, an anti-hypertensive drug, impedes JEV infection, possibly via the AT1/PPARγ axis. Microbiology Spectrum. 2025. doi:10.1128/spectrum.03003-24

BibTeX
@article{Datey2025,
  author = {Datey, Ankita and Chatterjee, Sanchari and Ghosh, Soumyajit and Kumar, P Sanjai and De, Saikat and Ghorai, Udvas and Hota, Debasish and Subudhi, Bharat Bhusan and Chattopadhyay, Soma},
  title = {Telmisartan, an anti-hypertensive drug, impedes JEV infection, possibly via the AT1/PPARγ axis},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.03003-24}
}
Kostenlos starten →